Phio Pharmaceuticals Enters $6.36 Million At-The-Market Offering Agreement with H.C. Wainwright
On April 8, 2026, Phio Pharmaceuticals Corp. entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. Under the terms of the agreement, the company may offer and sell shares of its common stock from time to time with an aggregate offering price of up to $6,360,000. H.C. Wainwright will act as the sales agent and will receive a commission of 3.0% of the gross proceeds from each sale. The shares will be issued pursuant to the companyβs existing shelf registration statement on Form S-3, which became effective on July 1, 2024. Phio Pharmaceuticals is under no obligation to sell any shares and may suspend or terminate the agreement at any time. The proceeds are intended for general corporate purposes. The filing also includes customary representations, warranties, and indemnification obligations between the parties. No specific timeline or volume for the sales was disclosed, as transactions will be conducted at the company's instruction based on market conditions.